EP12.02-06 Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC)

Lorlatinib, alectinib and brigatinib are next generation anaplastic lymphoma kinase (ALK) inhibitors (ALKis), for the treatment of advanced non-small-cell lung cancer (aNSCLC). In randomized controlled trials (RCTs), all demonstrated superior efficacy compared to crizotinib, a first-generation ALKi. Given the evolving treatment landscape of ALK+ aNSCLC, there is a need to evaluate the comparative efficacy and safety of second- and third-generation ALKis. In the absence of head-to-head RCTs, a formal indirect treatment comparison is required.